OncoMatch/Clinical Trials/NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Is NCT04822337 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin for multiple myeloma.
Treatment: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin — This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 del(17p)
del(17p)
Required: CDKN2C del(1p)
del(1p)
Required: IGH t(4;14)
t(4;14)
Required: IGH t(14;16)
t(14;16)
Required: IGH t(14;20)
t(14;20)
Required: RB1 monosomy 13
Monosomy 13
Required: RB1 del(13q)
del(13q)
Required: CKS1B gain(1q21) (>= 3 copies)
Gain of 1q21 [greater than or equal to 3 copies]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
Subjects with Relapsed or Relapsed/Refractory MM who have had at least 1 line of prior therapy
Cannot have received: monoclonal antibody
Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drug
Cannot have received:
Discontinuation of prior carfilzomib, lenalidomide or dexamethasone due to treatment toxicity
Lab requirements
Blood counts
Demonstrate adequate organ function
Kidney function
Demonstrate adequate organ function
Liver function
Demonstrate adequate organ function
Cardiac function
Adequate cardiac function as defined by a greater than 40% left ventricular ejection fraction (LVEF) by ECHO, cardiac MRI or MUGA
Demonstrate adequate organ function; Adequate cardiac function as defined by a greater than 40% left ventricular ejection fraction (LVEF) by ECHO, cardiac MRI or MUGA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Levine Cancer Institute · Charlotte, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify